- Home
- IBO vs NRSN Comparison
IBO vs NRSN Comparison
Compare IBO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- NRSN
- Stock Information
- Founded
- IBO 2018
- NRSN 2017
- Country
- IBO United States
- NRSN Israel
- Employees
- IBO N/A
- NRSN N/A
- Industry
- IBO
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- NRSN Health Care
- Exchange
- IBO NYSE
- NRSN Nasdaq
- Market Cap
- IBO 22.1M
- NRSN 26.0M
- IPO Year
- IBO 2024
- NRSN 2021
- Fundamental
- Price
- IBO $0.43
- NRSN $0.99
- Analyst Decision
- IBO
- NRSN Hold
- Analyst Count
- IBO 0
- NRSN 1
- Target Price
- IBO N/A
- NRSN N/A
- AVG Volume (30 Days)
- IBO 9.7M
- NRSN 130.1K
- Earning Date
- IBO 05-23-2025
- NRSN 04-07-2025
- Dividend Yield
- IBO N/A
- NRSN N/A
- EPS Growth
- IBO N/A
- NRSN N/A
- EPS
- IBO N/A
- NRSN N/A
- Revenue
- IBO N/A
- NRSN N/A
- Revenue This Year
- IBO N/A
- NRSN N/A
- Revenue Next Year
- IBO N/A
- NRSN N/A
- P/E Ratio
- IBO N/A
- NRSN N/A
- Revenue Growth
- IBO N/A
- NRSN N/A
- 52 Week Low
- IBO $0.37
- NRSN $0.51
- 52 Week High
- IBO $6.17
- NRSN $1.50
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- NRSN 44.13
- Support Level
- IBO N/A
- NRSN $0.97
- Resistance Level
- IBO N/A
- NRSN $1.04
- Average True Range (ATR)
- IBO 0.00
- NRSN 0.09
- MACD
- IBO 0.00
- NRSN 0.00
- Stochastic Oscillator
- IBO 0.00
- NRSN 57.04
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.